MRNA Quote, Financials, Valuation and Earnings

Biogen has a net margin of -907.48% compared to Moderna's net margin of 9.89%. Moderna's return on equity of -29.23% beat Biogen's return on equity of 9.11%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 77.18%. On the other hand Biogen has an analysts' consensus of $172.20 which suggests that it could grow by 35.26%. Given that Moderna has higher upside potential than Biogen, analysts believe Moderna is more attractive than Biogen.

Moderna has a beta of 1.858, which suggesting that the stock is 85.779% more volatile than S&P 500. In comparison Biogen has a beta of 0.144, suggesting its less volatile than the S&P 500 by 85.631%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biogen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Biogen pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Biogen quarterly revenues of $2.4B. Moderna's net income of -$971M is lower than Biogen's net income of $240.5M. Notably, Moderna's price-to-earnings ratio is -- while Biogen's PE ratio is 12.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.33x versus 1.90x for Biogen. Usually stocks with elevated PS ratios are considered overvalued.

Gilead Sciences has a net margin of -907.48% compared to Moderna's net margin of 19.72%. Moderna's return on equity of -29.23% beat Gilead Sciences's return on equity of 32.29%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 77.18%. On the other hand Gilead Sciences has an analysts' consensus of $116.77 which suggests that it could grow by 10.23%. Given that Moderna has higher upside potential than Gilead Sciences, analysts believe Moderna is more attractive than Gilead Sciences.

Moderna has a beta of 1.858, which suggesting that the stock is 85.779% more volatile than S&P 500. In comparison Gilead Sciences has a beta of 0.291, suggesting its less volatile than the S&P 500 by 70.86%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences offers a yield of 2.95% to investors and pays a quarterly dividend of $0.79 per share. Moderna pays -- of its earnings as a dividend. Gilead Sciences pays out 816.25% of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Gilead Sciences quarterly revenues of $6.7B. Moderna's net income of -$971M is lower than Gilead Sciences's net income of $1.3B. Notably, Moderna's price-to-earnings ratio is -- while Gilead Sciences's PE ratio is 22.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.33x versus 4.65x for Gilead Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -907.48% compared to Moderna's net margin of 50.24%. Moderna's return on equity of -29.23% beat Johnson & Johnson's return on equity of 30.18%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 77.18%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 11.1%. Given that Moderna has higher upside potential than Johnson & Johnson, analysts believe Moderna is more attractive than Johnson & Johnson.

Moderna has a beta of 1.858, which suggesting that the stock is 85.779% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.422, suggesting its less volatile than the S&P 500 by 57.846%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.3% to investors and pays a quarterly dividend of $1.30 per share. Moderna pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Moderna quarterly revenues are $107M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Moderna's net income of -$971M is lower than Johnson & Johnson's net income of $11B. Notably, Moderna's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 16.94x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.33x versus 4.14x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -907.48% compared to Moderna's net margin of -60.08%. Moderna's return on equity of -29.23% beat Sarepta Therapeutics's return on equity of -20.94%.

Moderna has a consensus price target of $47.59, signalling upside risk potential of 77.18%. On the other hand Sarepta Therapeutics has an analysts' consensus of $48.04 which suggests that it could grow by 175.14%. Given that Sarepta Therapeutics has higher upside potential than Moderna, analysts believe Sarepta Therapeutics is more attractive than Moderna.

Moderna has a beta of 1.858, which suggesting that the stock is 85.779% more volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Moderna has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Moderna pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Moderna quarterly revenues are $107M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Moderna's net income of -$971M is lower than Sarepta Therapeutics's net income of -$447.5M. Notably, Moderna's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Moderna is 3.33x versus 0.87x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.